Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The investment bank is establishing a corporate venturing unit that will invest $10m to $20m per deal in financial technology developers.

Illumina and Amgen-backed genomic sequencing technology developer Oxford Nanopore has added $59.6m to a round that now totals $98.1m.

OCD drug developer Exscientia bagged $60m in a Novo-led round that also featured Bristol-Myers Squibb and existing corporate investor Evotec.

Novo has led a $60m series C round for University of Dundee’s Exscientia that also attracted Evotec, Bristol-Myers Squibb, and GT Healthcare Capital.

Oxford Nanopore has added $59.6m to its latest funding round to bring the round to $98.1m and its overall funding to nearly $692m.

Nanoform has filed for a dual listing in Sweden and Finland, marking the first time that a University of Helsinki spinout is seeking an initial public offering.

The auto insurance provider secured $18.3m in a round led by CommerzBank’s investment arm that lifted its overall funding to more than $26m.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Liberty Global's corporate venturing unit owns half of a newly formed venture aimed at building electric vehicle charging points using underground telecommunications wiring.